our proprietary Carrierwave technology can be applied
in various ways to improve existing drugs. We refer to our
Carrierwave compounds as Conditionally Bioreversible
Derivatives (CBDs). We create a new moleculea derivativemade
of the active pharmaceutical ingredient of a drug such as
an amphetamine or opioid, covalently attached to an adjuvant.
We design the new molecules to be pharmacologically inactive
and only activated ("bioreversed") when taken as